IP Library Granted Patent US 11,783,914
Granted Patent B2
US 11,783,914 · App. 15/707,907 · Granted Oct 10, 2023

Method and system for panel characterizations

Inventors: Zachary Apte (San Francisco, CA); Jessica Richman (San Francisco, CA); Daniel Almonacid (San Francisco, CA); Laurens Kraal (San Francisco, CA); Francisco Ossandon (San Francisco, CA); Juan Pablo Cardenas (San Francisco, CA); Elisabeth Bik (San Francisco, CA); Audrey Goddard (San Francisco, CA)
Assignee: PSOMAGEN, INC.
G16B30/10G16B20/00G16B30/00G16B40/00G16B40/20G16H10/40G16H20/60G16H50/20Y02A90/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,783,914
App. No.
15/707,907
Granted
Oct 10, 2023
Kind
B2
Abstract

Embodiments of a system and method for characterizing a panel of conditions associated with a set of taxa related to microorganisms can include a taxonomic database including reference microbiome features for the set of taxa associated with the panel of conditions; a handling operable to collect a container including biological material from a user, the handling system comprising a sequencer system operable to determine a microorganism sequence dataset; and a panel characterization system operable to: determine user microbiome features for the set of taxa for the user based on the microorganism sequence dataset, generate a comparison between the user microbiome features and the reference microbiome features, and determine a panel characterization for the panel of conditions for the user based on the comparison; and a treatment system operable to promote a therapy for a condition of the panel of conditions based on the panel characterization.

Claims (23)

1. A method for characterizing a panel of microorganism-related conditions associated with a set of taxa, the method comprising:

generating a taxonomic database comprising reference features associated with the set of taxa;

generating a microorganism sequence dataset for a user based on a biological sample collected from the user;

extracting a set of panel-associated features for the user based on the microorganism sequence dataset and by applying feature-selection rules;

determining a comparison between the reference features and the set of panel-associated features for the user;

determining a panel characterization for the user for the panel of microorganism-related conditions based on the comparison; and

promoting a therapy for a microorganism-related condition of the panel of microorganism-related conditions, based on the panel characterization,

collecting a diet-associated supplementary dataset associated with a dietary behavior of the user, wherein promoting the probiotic consumable comprises promoting the probiotic consumable to the user based on the diet-associated supplementary dataset and the panel characterization,

wherein extracting the set of panel-associated features by applying the feature selection rules comprises extracting microbiome composition diversity features and microbiome functional diversity features of the set of panel-associated features based on the microorganism sequence dataset, and wherein determining the comparison comprises determining the comparison of the reference features with the microbiome composition diversity features and the microbiome functional diversity features,

wherein promoting the therapy comprises promoting a probiotics-related therapy for the microorganism-related condition, wherein the probiotics-related therapy is associated with the set of taxa, and wherein the set of taxa comprises at least one of: Bacillus coagulans (species), Bifidobacterium animalis (species), Clostridium butyricum (species), Lactobacillus brevis (species), Lactobacillus coryniformis (species), Lactobacillus fermentum (species), Lactobacillus helveticus (species), Lactobacillus rhamnosus (species), and Streptococcus salivarius (species).

2. The method of claim 1 , wherein the panel of microorganism-related conditions comprises a set of gut-related conditions associated with antibiotics, wherein extracting the set of panel-associated features comprises extracting microbiome pharmacogenomics features of the set of panel-associated features based on the microorganism sequence dataset, and wherein promoting the therapy comprises promoting an antibiotics-associated therapy for the set of gut-related conditions based on the microbiome pharmacogenomics features.

3. The method of claim 1 , wherein determining the comparison between the reference features and the set of panel-associated features comprises determining the set of panel-associated features as associated with at least one of: presence of microbiome composition features, absence of the microbiome composition features, relative abundance for taxonomic groups of the set of taxa, diversity of microbiome composition including taxonomic and functional features, a ratio between at least two features associated with the set of taxa, interactions between the taxonomic groups, and phylogenetic distance between the taxonomic groups.

4. The method of claim 3 , wherein generating the taxonomic database comprises determining a set of reference relative abundance ranges for the set of taxa, wherein the set of reference relative abundance ranges is associated with the panel of microorganism-related conditions,

wherein extracting the set of panel-associated features comprises extracting a set of user relative abundance ranges for the set of taxa based on the microorganism sequence dataset, and

wherein determining the comparison between the reference features and the set of panel-associated feature comprises determining the comparison between the set of reference relative abundance ranges and the set of user relative abundance ranges.

5. The method of claim 4 , wherein determining the set of reference relative abundance ranges for the set of taxa comprises:

collecting a set of supplementary biological samples and a set of supplementary datasets for a population of users;

processing the set of supplementary biological samples to generate a supplementary microorganism sequence dataset using a set of primers associated with the panel of microorganism-related conditions; and

determining the set of reference relative abundance ranges based on the supplementary microorganism sequence dataset and the set of supplementary datasets.

6. The method of claim 3 , wherein determining the comparison between the reference features and the set of panel-associated features comprises performing at least one of: a prediction analysis, multi hypothesis testing, a random forest test, principal component analysis, significance index analysis, risk score analysis, and meta-analysis.

7. The method of claim 1 , wherein the set of taxa further comprises at least one of: Acetobacter nitrogenifigens (species), Azospirillum brasilense (species), Bacillus licheniformis (species), Bifidobacterium bifidum (species), Brevibacillus laterosporus (species), Clavibacter michiganensis (species), Enterococcus italicus (species), Kocuria rhizophila (species), Lactobacillus delbrueckii (species), Lactobacillus kefiranofaciens (species), Lactobacillus kunkeei (species), Lactobacillus salivarius (species), Lactococcus garvieae (species), Lactococcus lactis (species), Leptotrichia hofstadii (species), Leuconostoc fallax (species), Leuconostoc kimchii (species), Oenococcus oeni (species), Paenibacillus apiarius (species), Pediococcus pentosaceus (species), Propionibacterium freudenreichii (species), Pseudoclavibacter helvolus (species), Renibacterium salmoninarum (species), Ruminococcus flavefaciens (species), Staphylococcus sciuri (species), Streptococcus dysgalactiae (species), Streptococcus parauberis (species), and Weissella koreensis (species).

8. The method of claim 1 , wherein the panel of microorganism-related conditions comprises at least one of: Diarrhea, Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis, Constipation, Abdominal Tenderness, Bloating, Flatulence, Obesity, Type II Diabetes, Prediabetes, Kidney Stones, Cardiovascular health, and Anxiety.

9. The method of claim 1 , wherein characterizing the panel of microorganism-related characterization comprises at least one of diagnosing and treating a gut-related panel of conditions.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2020
From: UBIOME, INC.
To: PSOMAGEN, INC.
Reel/Frame 051586/0274 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2018
From: APTE, ZACHARY; RICHMAN, JESSICA; ALMONACID, DANIEL; KRAAL, LAURENS; OSSANDON, FRANCISCO; CARDENAS, JUAN PABLO; BIK, ELISABETH; GODDARD, AUDREY
To: UBIOME, INC.
Reel/Frame 045285/0699 →
Continuity (14)
Continuation In Part 15606743 · May 26, 2017
Continuation In Part 14919614 · Oct 21, 2015
Provisional Application 62525379 · Jun 27, 2017
Provisional Application 62520058 · Jun 15, 2017
Provisional Application 62395939 · Sep 16, 2016
Provisional Application 62206654 · Aug 18, 2015
Provisional Application 62147362 · Apr 14, 2015
Provisional Application 62147376 · Apr 14, 2015
Provisional Application 62147212 · Apr 14, 2015
Provisional Application 62146855 · Apr 13, 2015
Provisional Application 62092999 · Dec 17, 2014
Provisional Application 62087551 · Dec 4, 2014
Provisional Application 62066369 · Oct 21, 2014
Related Publication 20180137239A1 · May 17, 2018